Volume 141, Issue 4, Pages 1212-1219 (October 2011) Entecavir Monotherapy Is Effective in Suppressing Hepatitis B Virus After Liver Transplantation James Fung, Cindy Cheung, See–Ching Chan, Man–Fung Yuen, Kenneth S.H. Chok, William Sharr, Wing–Chiu Dai, Albert C.Y. Chan, Tan–To Cheung, Simon Tsang, Banny Lam, Ching–Lung Lai, Chung–Mau Lo Gastroenterology Volume 141, Issue 4, Pages 1212-1219 (October 2011) DOI: 10.1053/j.gastro.2011.06.083 Copyright © 2011 AGA Institute Terms and Conditions
Figure 1 (A) Cumulative rate of HBsAg seroclearance. (B) Cumulative rate of HBsAg seroclearance in patients with and without HBV DNA level <5 log copies/mL and HBsAg level <3 log IU/mL. (C) Cumulative rate of HBsAg seroclearance in patients with and without detectable anti-HBs after liver transplant. (D) Cumulative rate of HBsAg relapse after initial seroclearance. Gastroenterology 2011 141, 1212-1219DOI: (10.1053/j.gastro.2011.06.083) Copyright © 2011 AGA Institute Terms and Conditions
Figure 2 Levels of HBV DNA at the time of liver transplant and at 1 to 3, 6, 12, and 24 months after transplant. Gastroenterology 2011 141, 1212-1219DOI: (10.1053/j.gastro.2011.06.083) Copyright © 2011 AGA Institute Terms and Conditions